Genmab — Marts 2019
-
-
-
God morgen
-
Investtech: Genmab har brudt op gennem loftet i en faldende trendkanal på mellemlang sigt. Dette indikerer i første omgang svagere faldende takt, eller indledning til en mere horisontal udvikling. Aktien gav købssignal fra en omvendt-hovede-og-skuldre-formation ved bruddet op gennem modstanden ved 1103. Videre stigning til 1571 eller mere er signaleret. Aktien nærmer sig støtten ved cirka 1110 kroner, noget der kan give en reaktion op. Aktien anses samlet set teknisk positiv på mellemlang sigt.
-
-
Også Celgene i MS. Der er kamp om det. https://m.firstwordpharma.com/hot-heels-eu-application-celgene-files-us-clearance-ozanimod-relapsing-multiple-sclerosis
-
God morgen
-
from recent Conference, Tisotumab vedotin
https://www.mdedge.com/hematology-oncology/article/197472/gynecologic-cancer/tisotumab-vedotin-shows-promise-recurrent
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind